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Summary
The signal transduction and gene expression network of the Bcr-Abl fusion ty-
rosine kinase, that causes Chronic myelogenous leukemia (CML) are only poorly
understood. In this diploma thesis certain aspects of the Bcr-Abl signaling should
be analyzed. The project mainly focused on two questions:
One aim was the identification of proteins, that are quickly and prominently up-
or down-regulated upon drug induced inhibition of Bcr-Abl to serve as mark-
ers for Bcr-Abl activity in Chronic myelogenous leukemia (CML). Such markers
could be helpful to easily monitor response to drug therapy of patients suffer-
ing from CML. In contrast to current methods, faster adaption of therapy to each
individual patient would be possible.
Using microarray analysis, more than 800 genes were identified to be differen-
tially regulated after Dasatinib treatment in K562 cells. Out of this list, 27 genes
were validated on RNA level by qRT-PCR including very interesting candidates
that have been previously reported to play a role in the development of cancer
or to be involved in Bcr-Abl signaling. Two proteins, the surface receptor CD69
and the cytokine IL8 have successfully been studied on protein level. They could
be shown to be down-regulated upon Bcr-Abl inhibition by either Dasatinib or
Nilotinib, two Bcr-Abl kinase inhibitors approved for treatment of CML patients.
CD69 was investigated in K562 cells, down-regulation of IL8 was shown in two
different Bcr-Abl expressing cell lines. Similar results could be obtained for serum
samples of a small cohort of CML patients, IL8 levels are elevated at the time-
point of diagnosis and decline in the course of drug therapy.
The second part of the project involves the investigation of Bcr-Abl core inter-
actors and their role in Bcr-Abl signal transduction. Detailed knowledge of the
Bcr-Abl signaling is important for the development of alternative CML therapy
possibilities.
III
Knock-down experiments of the core interactors should help to reveal their func-
tion in signal transduction. RNA interference protocols were successfully estab-
lished for K562 and UT7 p210 cells. Even though a knock-down was achieved for
every single core interactor on protein level, phenotypic changes could not have
been observed.
In this thesis, the results are discussed and analyzed in detail, proposals for con-
tinuation of the project are given.
IV
Zusammenfassung
Die Signaltransduktion und das Genexpressionsnetzwerk der Bcr-Abl Fusions-
Tyrosinkinase, die zu Chronisch Myeloider Leukämie (CML) führt, sind nur im
Ansatz aufgeklärt. In der vorliegenden Diplomarbeit wurden bestimmte Aspekte
des Bcr-Abl Signalings untersucht. Im Wesentlichen wurden im Rahmen dieses
Projektes die folgenden zwei Fragestellungen behandelt:
Zum einen solltenMarkergene beziehungsweiseMarkerproteine für diewirkstoff-
abhängige Hemmung von Bcr-Abl identifiziert werden. Solche Marker wären
hilfreich, um den Therapieerfolg von Patienten, die an CML leiden, zu verfolgen.
Im Gegensatz zu derzeitigen Methoden könnte die Therapieart schneller an jeden
einzelnen Patienten angepasst werden.
Mithilfe eines Microarrays wurden mehr als 800 Proteine identifiziert, die in K562
Zellen nach Wirkstoffbehandlung reguliert werden. Aus dieser Liste konnten
27 Gene mittels qRT-PCR erfolgreich auf RNA-Ebene verifiziert werden. Einige
davon wurden bereits mit verschiedenen Krebsarten in Zusammenhang gebracht
oder sind sogar im Bcr-Abl Signaling lokalisiert. Für zwei Proteine, CD69 und
IL8, konnte auch auf Proteinebene Regulierung in Abhänigkeit von Behandlung
mit Dasatinib oder Nilotinib, zwei zugelassenen Medikamenten für die Behand-
lung von CML, gezeigt werden. Mittels FACS Analyse wurde bestätigt, dass
nach Wirkstoffbehandlung weniger CD69 in K562 Zellen exprimiert wird. Eine
Senkung der IL8-Sekretion wurde in zwei verschiedenen Bcr-Abl positiven Zell-
linien detektiert. Auch die Untersuchung von Serumsproben einiger CML Pa-
tienten zeigte den Trend, dass die IL8-Level bei Diagnose erhöht sind, jedoch im
Verlauf der Therapie sinken.
Der zweite Teil des Projekts bestand darin, die Rolle der engsten Bcr-Abl Inter-
aktoren in dessen Signaling zu untersuchen. Für die Entwicklung neuer Thera-
pieansätze ist es wichtig, die Signalkaskaden von Bcr-Abl genau zu kennen.
V
Knock-down-Experimente der einzelnen Interaktoren sollten helfen, die Notwen-
digkeit dieser Proteine für die Bcr-Abl Signalübertragung aufzuklären. Protokolle
für RNA-Interferenz in K562 Zellen und UT7 p210 Zellen wurden erfolgreich
etabliert. Obwohl für alle Interaktoren ein Knock-down auf Proteinebene erzielt
werden konnte, wurden keine phänotypischen Auswirkungen festgestellt.
Die Ergebnisse werden in diese Arbeit genau analysiert und diskutiert, Möglich-
keiten für die Fortführung beider Projekte werden präsentiert.
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1. Introduction
1.1. Leukemia
The word “Leukemia” is derived from the greek words “leukos” and “haimos”
and means “white blood”. Leukemia describes a form of cancer, that affects
hematopoietic stem cells of the bone marrow. The disease is characterized by an
increased clonal proliferation of non-mature hematopoietic cells. Several factors
including chemicals, ionizing radiation, oncogenic viruses and genetic disposi-
tion may increase the risk for disease development [1].
A description of the disease was first given by Rudolf Virchov in 1847. Due to
his observations of the unusual composition of the blood with a predominant
portion of white blood cells and only a small amount of erythrocytes, he called
the disease “Weißes Blut” or “Leukämie”[2].
Figure 1.11 shows a comparison of normal peripheral blood (a) and the blood of
a leukemia patient (b). The blood of the healthy donor contains mainly erythro-
cytes (red) and only a low number of leukocytes (purple), while the blood sample
of the leukemia patient shows high concentration of leukocytes.
The accelerated production of leukocytes leads to an impairment of hematopoiesis
as the leukocytes infiltrate the bone marrow. This causes a decrease in erythro-
cyte and platelet concentration and an imbalance in the composition of blood. As
a consequence, patients suffer from anemia, the oxygen transport from the lung
to the periphery is insufficient. The lack of platelets impairs blood clotting after
injury. The leukocytes are often immature or non-functional and therefore the
function of the immune system can also be decreased.
1picture from: http://www.deutsches-museum.de/dmznt/ersatzteile/blut/blutbilder/index.html,
30.01.2007
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(a) Blood of healthy donor
(b) Blood of CML patient
Figure 1.1: Accumulation of leukocytes in the blood of a leukemia patient (red: erythro-
cytes, purple: leukocytes)
According to disease progression, stage of maturation and lineage of pathologi-
cally modified leukocytes, leukemia can be classified into four major types [3]:
• Acute lymphocytic leukemia (ALL)
• Chronic lymphocytic leukemia (CLL)
• Acute myelogenous leukemia (AML)
• Chronic myelogenous leukemia (CML)
Lymphocytic leukemias are characterized by an accelerated production of cells of
the lymphocytic lineage (B + T lymphocytes), whereas in myelogenous leukemia,
the number of cells of the myeloid lineage (mainly granulocytes) dramatically
increases.
2
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Acute leukemias progress very fast and lead to death within a couple of weeks
when untreated. They are characterized by an overproduction of immature pro-
genitor cells. The production of healthy mature cells is impaired. Chronic leuke-
mias proceed over a couple of years. Accumulation of mature white blood cells is
detected. The disease progresses very slowly and patients suffering from chronic
leukemias often need not to be treated in the first stages of the disease [3].
1.1.1. Chronic myelogenous leukemia
Chronic myelogenous leukemia (CML) is a pluripotential stem cell disease char-
acterized by the excessive proliferation of cells of the myeloid lineage. The dis-
ease is caused by a reciprocal translocation between chromosomes 9 and 22, lead-
ing to the expression of the Bcr-Abl fusion oncogene. The gene product is a con-
stitutively active tyrosine kinase. The Bcr-Abl signaling leads to an accelerated
cell proliferation signal.
An overview over the hematopoietic lineage and the development of CML is
given in figure 1.22. Hematopoietic stem cells, located in the bone marrow, give
rise to the cells of the myeloid lineage (myeloid progenitors) and cells of the lym-
phoid lineage (lymphoid progenitors). The myeloid progenitors further differ-
entiate into granulocyte/macrophage progenitors ormegakaryocyte/erythrocyte
progenitors. As the name already implies, granulocyte/macrophage progenitors
can either differentiate intomature granulocytes ormacrophageswhilemegakary-
ocyte/erythrocyte progenitors differentiate into erythrocytes or megakaryocytes
(which in turn give raise to platelets) [4].
The progression of CML is characterized by three main stages, a chronic stage fol-
lowed by an accelerated stage ending up in blast crisis. During the chronic phase,
with an average duration of 3-4 years the granulocytic cell lineage massively ex-
pands. The granulocytes of patients are positive for Bcr-Abl. In blast crisis, cell
differentiation is blocked and immature myeloid or lymphoid precursors (also
called blast cells) accumulate in the peripheral blood or the bone marrow. Blast
crisis leads to death after 3-6 months. Up to now, bone marrow transplantation is
the only curative therapy of CML [4, 5].
2figure adopted from [4]
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The Bcr-Abl protein is necessary for the development and the maintenance of the
disease, yet, the switch from chronic phase to accelerated phase and blast crisis
requires accumulation of additional abnormalities [4].
Figure 1.2: Development of CML (HSC hematopoietic stem cell, MP myeloid progen-
itor, LP lymphoid progenitor, G/MP granulocyte/macrophage progenitor, M/EP
megakaryocyte/erythrocyte progenitor, G granulocyte, M macrophage, E erythro-
cyte, MK megakaryocyte, P platelet)
1.1.1.1. Epidemiology
Chronic myelogenous leukemia accounts for about 15% of all adult leukemias.
The world-wide case-incidence varies from 1-2 cases per 100 000 persons a year.
Incidences increase with age, median age at time of first show is about 40-60. The
disease rarely occurs in children. Men are more often diagnosed with the disease,
than women (approximate ratio 1,4 : 1) [2, 6].
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1.2. The Bcr-Abl fusion protein
CML results from a reciprocal translocation between chromosomes 9 and 22 (t(9;22)
(q34;q11)). The translocation leads to the formation of a shortened long arm of
chromosome 22 the so-called Philadelphia (Ph) chromosome (see figure 1.3). On
the molecular level, this mutation leads to the fusion of the 5’ part the Break-
point cluster region (Bcr gene) that remains on chromosome 22 to the 3’ part of
the c-Abl gene deriving from chromosome 9. The new chimeric gene is called the
Bcr-Abl oncogene and it codes for a constitutively active tyrosine kinase [2].
Figure 1.3: Reciprocal translocation between Chromosomes 9 and 22 leading to the for-
mation of the Philadelphia chromosome carrying the Bcr-Abl fusion gene
Depending on the exact translocation breakpoints, Bcr-Abl proteins with different
molecular weights are formed. Tree main breakpoint regions were identified on
chromosome 22. The Bcr-Abl fusion protein is either a 210 kDa-protein (Bcr-Abl
p210), a 190 kDa-protein or a 230 kDa-protein. All the forms contain the same
part of the c-Abl gene but the Bcr-part varies in size. The vast majority of CML
patients express Bcr-Abl p210 [2].
In approximately 20% of all cases of B-ALL (B-cell ALL) the Bcr-Abl protein also
appears, called Philadelphia chromosome positive ALL (Ph+ ALL). Bcr-Abl p190
appears in most of the cases of Ph+ ALL (about two thirds of cases), Bcr-Abl p210
is detected in one third of the cases [2].
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1.2.1. Regulation and signaling of the Bcr-Abl fusion protein
The Bcr-Abl protein is a huge protein carrying a variety of functional domains
(see figure 1.4).
Figure 1.4: Domains of Bcr-Abl
1.2.1.1. c-Abl
The c-Abl protein is a non-receptor tyrosine kinase. It has been reported to play
a role in regulation of cell growth and survival, oxidative stress, DNA-damage
response, actin dynamics and cell migration [7].
c-Abl carries Src-homology-2 (SH2), Src-homology-3 (SH3) and tyrosine kinase
domains, which are conserved among members of the Abl family (c-Abl and
Arg), Src-family (nine members) and Tec family (five members). The Abl fam-
ily members furthermore have a long carboxy-terminal tail, the last exon region,
which contains protein-protein interaction sites and subcellular localization mo-
tifs. Proline rich binding-sites in the tail mediate binding of SH3 domains of adap-
tor proteins. Furthermore, the last exon region also hosts a DNA-binding domain
and an F-actin binding domain. Three nuclear localization signals (NLS) enable
nuclear import of c-Abl [7].
The c-Abl kinase is a very tightly regulated protein. The domains interact with
each other in a very complex manner, leading to an auto-inhibited form of c-Abl.
Amongst others, interactions occur between the SH3 domain and the linker seg-
ment, that connects the SH2 domain with the kinase domain. The SH2 domain
contacts the kinase domain via hydrogen bonds. In the autoinhibited confor-
mation, the SH3 domain and the SH2 domain form a “clamp” and the activa-
tion loop of the kinase domain blocks binding of the substrate and ATP. When
6
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autoinhibited, c-Abl is not phosphorylated on tyrosine residues. In c-Abl 1b,
an N-terminal myristoyl group is necessary for maintaining the autoinhibited,
non-phosphorylated structure, it remains unclear which moieties substitute the
function of the myristoyl group in the alternative spliceform c-Abl 1a that is not
myristoylated. Phosphorylation of a tyrosine residue in the activation loop leads
to a conformational change and is necessary to activate c-Abl [7].
In the Bcr-Abl fusion protein, the very N-terminal part of Abl is missing, the Bcr-
moiety elongates the protein instead. Except from the myristoyl group, all the
functional domains of c-Abl are also present in Bcr-Abl and the fusion protein
shows very similar intramolecular interactions as c-Abl [7].
1.2.1.2. Bcr
Although the Breakpoint cluster region was excessively studied, the exact func-
tion of the Bcr gene remains unclear. Different transcript versions and isoforms
have been identified. The protein consists of an N-terminal coiled-coil domain,
a Rho-GAP and a Rho-GEF domain. Furthermore, the protein contains binding
sites for a number of important signaling proteins [8].
Depending on the translocation breakpoint, part of the Bcr protein can also be
found on the Bcr-Abl protein. Through the N-terminal coiled-coil domain, de-
riving from the Bcr-moiety, Bcr-Abl is able to form dimers and tetramers. This
oligomerization enables Bcr-Abl to trans-autophosphorylate the activation loop
of Abl, which is the main contribution to its costitutive activity. As for c-Abl this
phosphorylation is necessary to activate the kinase [4, 7].
1.2.1.3. Protein-protein interactions and activation of signaling pathways
Bcr-Abl interacts with a large variety of signaling proteins. The fusion of c-Abl
and Bcr leads to the formation of a huge platform that permits binding of a large
number of proteins that are then phosphorylated and turn on numerous of im-
portant signaling pathways (e.g.: Ras-MAPK, PI3K/AKT, Jak-STAT,...), which
then activate a range of transcription factors (e.g.: NF-κB, MYC, STATs,...). This
changes the gene expression pattern of the cells and leads to hyperproliferation.
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The exact mechanism of how these signaling pathways are activated by Bcr-Abl
and which proteins are crucial for the signal transduction is only poorly revealed.
A number of direct and indirect interactors of Bcr-Abl have been identified, in-
cluding Grb2, Cbl and subunits of the PI3-kinase [2]. Several core interactors
signal into the same pathways. The stoichiometric composition and the exact
interaction network of the core interactome remains unclear.
It is still not fully understood, which interactions are crucial to preserve the can-
cerous signaling of Bcr-Abl.
1.2.2. Inhibition of Abl and Bcr-Abl
1.2.2.1. Imatinib
Imatinib (also called STI571) was the first identified selective inhibitor of the Abl
proteins. The phenylaminopyrimidine derivate specifically binds and inhibits
autophosphorylation of three kinases: Abl, c-Kit and PDGF-receptor.
Imatinib binds to the ATP pocket when the Abl-kinase domain is in its inactive
conformation and the activation loop blocks the ATP binding site. This specific
binding is crucial for the selectivity over closely related kinases like Src [9].
The strong inhibitory function of Imatinib on Bcr-Abl induces growth arrest and
apoptosis in Bcr-Abl positive cell lines, but not in Bcr-Abl negative cell lines. Mice
injected with the human, myeloid Bcr-Abl+ cell line KU812 and treated with Ima-
tinib showed a tumor-free survival, whereas growth of injected U937 cells (a Bcr-
Abl negative myeloid human cell line) was not inhibited in growth by Imatinib
[10].
During the clinical trails, more than 96% of Imatinib-treated CML patients in
chronic phase respond to Imatinib treatment with complete hematologic response
(CHR, normalization of white blood cell counts), about 69% of patients showed
complete cytogenetic response (CCR, 0% Ph+ cells in bone marrow) after one year
treatment [11]. The high inhibitory potency of Imatinib and the relative low side
effects led to an exceptionally fast approval of the drug for CML treatment by the
US Food and Drug Admimistration (FDA) in 2001, less than three years after start
8
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of Phase I clinical studies. As the drug also inhibits c-Kit, which is an oncogene
leading to gastrointestinal stromal tumor (GIST), it was approved for therapy of
GIST patients, too. Imatinib was developed by Novartis and is sold under the
trade name “Gleevec” [9].
Resistance to Imatinib Availability of Imatinib is a great step in the treatment
of CML, still it has some disadvantages. First, constant drug treatment is nec-
essary, as the Bcr-Abl positive clones of hematopoietic stem cells are not com-
pletely eliminated. Second, resistances to Imatinib occur. A few patients do not
respond to Imatinib treatment at all (primary resistance), others develop resis-
tance after primary response and the disease again progresses (secondary resis-
tance). Mutations in the Bcr-Abl gene kinase domain lead to insensitivity to the
drug. These mutations can affect the drug binding residues themselves, as well
as distant amino acids leading to conformational changes that prevent Imatinib
binding (allosteric inhibition). Both, primary and secondary resistance are more
common in patients with an advanced stage of the disease [7, 10].
1.2.2.2. Second generation inhibitors
A lot of effort was made to develop Abl-inhibitors that also target mutated forms
of Bcr-Abl. This led to the development of Dasatinib (BMS-354825) and Nilotinib
(AMN-107). Both bind, like Imatinib, to the ATP-binding site of the Abl-kinase
domain and are able to induce cell death in Bcr-Abl positive cells.
Dasatinib Dasatinib was developed by Bristol-Myers Squibb and it is sold as
“Sprycel”. Based on another chemical structure than Imatinib, Dasatinib is a
less selective kinase inhibitor than Imatinib, also targeting Src family kinases and
many other Tyr- and Ser/Thr-kinases. In 2006, Dasatinib was approved for the
treatment of CML patients insensitive to Imatinib in the US and in the EU. The
drug has a 325-fold greater potency than Imatinib for wild-type Bcr-Abl and leads
to hematologic and cytogenetic responses in CML patients in all stages of the dis-
ease [5]. Moreover, Dasatinib can inhibit all tested Bcr-Abl resistance mutations
except the T315I mutation. Another advantage of Dasatinib is its inhibitory effect
on Src family kinases which may play a role in disease progression [12, 13].
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Nilotinib Nilotinib, a derivative of Imatinib, developed by Novartis is sold un-
der the trade name “Tasigna”. Since 2007 it is approved for the treatment of
Imatinib-insensitive CML patients in the US and the EU. Nilotinib is a very se-
lective inhibitor, targeting the same kinases as Imatinib. It binds the Abl-kinase
domain more tightly and therefore has 30-50 times greater potency than Imatinib
[5]. Like Dasatinib, it is able to inhibit all tested Bcr-Abl mutations except the
T315I mutation. Effective Nilotinib therapy was observed during all phases of
disease, responses were higher in earlier stages of disease [14].
Other inhibitors Several other potent Bcr-Abl inhibitors have already been de-
veloped, currently in pre-clinical or early clinical test phase. Some of them are
able to inhibit T315I mutated Bcr-Abl. Another possibility to treat CML is target-
ing downstream signaling proteins of Bcr-Abl. This requires exact understanding
of the Bcr-Abl signaling machinery [5].
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2. Aim of the project
2.1. Changes in gene expression induced by
Bcr-Abl
As already mentioned, Bcr-Abl is a constitutively active tyrosine kinase, that
leads to a permanent pro-proliferative and anti-apoptotic signal. Up to know,
the signaling pathways and the target genes of Bcr-Abl are not fully understood.
The state of activity and the expression levels of proteins, that regulate the cell
cycle must be altered in a way to avoid apoptosis and push growth and cell di-
vision. In CML, the differentiation of the myeloid precursors into active, mature
cells is impaired by blocking differentiation signaling.
If Bcr-Abl directly alters the activity or expression of a transcription factor, this in
turn leads to changes in the expression of the targets of the transcription factor.
Certain genes can be either up- or down regulated.
As soon as Bcr-Abl activity is blocked by a specific drug, the signaling is shut
down and the cells die after a certain time. The alteration in gene expression in
comparison to Bcr-Abl negative cells should come back to a normal level.
2.1.1. Identification of markers for Bcr-Abl activity
The primary aim of the project was to identify a set of biological makers that can
be used as a read-out system for drug-dependent Bcr-Abl inhibition in cell lines,
as well as in bone marrow or serum from CML patients. The goal was to find a set
of proteins that are significantly up- or down-regulated as a consequence of Bcr-
Abl inhibition due to drug treatment. Ideally, these proteins should be secreted
by the cells or expressed on the cell surface to be easily detectable.
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The regulation of the candidate genes should be shown on both, RNA and protein
level. A set of potential candidate genes was obtained using a DNA-microarray.
First, the data should be confirmed using quantitative real-time PCR (qRT-PCR).
As a second step, the regulation should also be shown on protein level using
western blotting, flow cytometry analysis or ELISA, depending on the cellular
localization of the candidate protein.
Up to now, the effect of drug therapy in CML patients is tested via white blood
cell count or analysis of Bcr-Abl expression in leukocytes. The identification of a
marker for drug-dependent inhibition of Bcr-Abl after a short period of treatment
could help to develop a method to test the effect of the drug faster than via the
established methods.
2.1.2. Functional validation of Bcr-Abl core interactors
The signaling of Bcr-Abl runs via signaling cascades involving a broad range of
proteins and finally reaches the cell nucleus to change gene expression. The most
abundant interactors of Bcr-Abl were previously identified by pull down experi-
ments. The exact binding sites and the stoichiometry of this so-called core inter-
actor complex is not known so far. Another question is, if the interaction between
the single core proteins and Bcr-Abl is essential for Bcr-Abl signaling. To ap-
proach this problem, the core interactor proteins should be knocked-down using
RNA interference. The influence of the knock-down on the survival and prolifer-
ation of the cell should give information about the functional involvement in the
Bcr-Abl signaling cascade. As the core interactome of Bcr-Abl was identified in
K562 cells, the functional validation should also be done in the same cell line.
The determination of critical interactors could lead to the identification of new
therapy targets in CML downstream of Bcr-Abl to overcome drug-insensitive Bcr-
Abl mutations.
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3.1. Cell biology
3.1.1. Cell lines and cell culture
K562 humanCML cell line expressing endogenous Bcr-Abl, established from
a CML patient in blast crisis
U937 human monocytic cell line, established from a patient with histiocytic
lymphoma
UT7 par human CLL cell line, dependent on GM-CSF
UT7 p210 human CLL cell line, stably transected with Bcr-Abl, independent of
GM-CSF
All cell lines were cultured at 37°C in a 5% CO2 incubator. Cells were kept at
subconfluency by splitting them every 2-3 days.
K562 cells, U937 cells and UT7 p210 cells were cultured in RPMI (Invitrogen)
supplemented with 10% fetal calf serum (FCS) (Invitrogen). UT7 par cells were
supplemented with additional 2 ng/ml human GM-CSF (R&D Systems).
3.1.1.1. RNA interference
For each Bcr-Abl core interactor a SMARTpool siRNA was purchased from Dhar-
macon. To target Bcr-Abl itself, a b3a2 breakpoint specific siRNA (BAF 7) and
a control siRNA with 3 missmatches (BAF 8) were ordered from Dharmacon
[15]. According to the manufacturer’s instructions the siRNAs were dissolved
in siRNA buffer (Dharmacon) to obtain a 20 µM stock solution and kept at -20°C.
( See appendix, table A.1 for siRNA sequences of BAF7 and BAF8.)
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Gene knock-down in K562 cells The day before transfection confluent cells
were split 1:4 to push the cells into logarithmic growth phase. The day of trans-
fection 1x106 cells were resuspended in 500 µl medium and seeded into a 6-well
plate. 5 µl siRNA solution and 18 µl HiPerFect were combined with 500 µl serum
free RPMI. The solution was mixed well by vortexing and incubated for 7 min
at room temperature to allow formation of complexes. Then, the siRNA mixture
was added to the cells dropwise during shaking of the plate. This leads to an
siRNA concentration of 100 nM. 6 hours after transfection 2 ml of medium were
added to the cells. Cells were either harvested 48 h after transfection or the trans-
fection procedure was repeated 24 h after primary transfection and cells were
finally harvested 72 h after primary transfection.
Gene knock-down in UT7 p210 cells UT7 p210 cells were transfected using
the Amaxa electroporation system. 1x106 cells were resuspended in 200 µl Amaxa
Nucleofactor solution V and 5 µl siRNA were added to the cell suspension (lead-
ing to a 500 nM siRNA solution). The mixture was transferred into Amaxa cu-
vettes and transfected using program X-001 of the Amaxa Nucleofector. Then, 1
ml RPMI + 10% FCS was added to the cell suspension and transferred into a 6-
well plate containing 2 ml pre-warmed RPMI +10% FCS and incubated on 37°C.
Knock-down was analyzed 48 h after transfection.
3.1.1.2. Drug treatment of cells
The kinase inhibitors Dasatinib (Sprycel, BMS-354825) and Nilotinib (Tasigna,
AMN107) were synthesized by WuXi PharmaTech (Shanghai, China). 20 mM
stock solutions of the kinase inhibitors were prepared in DMSO and diluted in
the respective cell culture medium to final concentrations of 100 nM for Dasa-
tinib and 1 µM for Nilotinib.
Subconfluent cells were treated with the drugs for 3 hours for RNA isolation or
up to 24 h for western blot analysis, flow cytometry analysis or ELISA.
14
3. Material and Methods
3.2. Genomic analysis
3.2.1. RNA extraction from cell lines
RNA was purified using the RNeasy Mini Kit (Qiagen) in combination with QIA-
shredder columns (Qiagen) following the manufacturer’s instructions. If real-
time PCR was to be performed, RNA was digested with DNase (Fermentas) to
eliminate a potential genomic DNA contamination. To determine RNA quantity,
the absorbance was measured at 260 nm in a spectrophotometer. RNA quality
was verified by running 5 µl of RNA sample after DNase digestion diluted 1:1,5
in loading buffer on a 1 % agarose (Sigma) gel in TAE and checking for integrity
of the 28S and 18S rRNA bands.
Loading buffer 8 ml formamide
20 µl 0,5 M EDTA
1,98 ml RNAse-free water
TAE 40 mM Tris
40 mM acetic acid
1 mM EDTA
3.2.2. MicroRNA extraction from cell lines
For isolating microRNA (miRNA), the mirVana™ miRNA Isolation Kit from Am-
bion was used, extraction was performed by following the manufacturer’s proto-
col. This kit allows the isolation of small RNA-containing total RNA, it includes
organic extraction followed by purification on a glass fiber filter.
3.2.3. Quantitative real-time PCR (qRT-PCR)
For reverse transcription 1 µg RNA and 0,5 µg oligo(dT)18 primer (Fermentas) in
a total volume of 11 µl were heated for 5 min at 70°C, then chilled on ice. Next,
4 µl 5x reaction buffer (Fermentas), 2 µl 10 mM dNTPs, 20 U RNasIn ribonucle-
ase inhibitor (Promega) and water were added to reach a final volume of 19 µl.
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The mix was incubated at 37°C for 5 min. 1 µl 200 U/µl RevertAid™ M-MuLV
Reverse Transcriptase (Fermentas) was added to each reaction and incubated at
42°C for 1 h. The enzyme was heat-inactivated at 70°C for 10 min.
Quantitative real-time PCR was performed with iTaq SYBR Green Supermix With
ROX (Bio-Rad) as detection chemistry using a 7700 cycler (Applied Biosystems)
or a Rotor-Gene 6000 (Corbett). Primer sequences are listed in the appendix (table
A.2).
For each qRT-PCR reaction 10 µl iTaq SYBR Green Supermix, 0,5 µl 10 µM primer
mix, 4,5 µl water and 5 µl 1:20 diluted cDNA were combined by hand or using the
CAS-1200 liquid handling system (Corbett). PCRs were run with the following
thermoprofile: Initial denaturation at 95°C for 3 min; then 40 cycles of 94°C 30 sec,
60°C 15 sec and 72°C 30 sec. Melting curves were checked after each run to detect
potential primer dimers and contaminations. Using GAPDH as a reference gene,
evaluation of expression changes was performed via calculation of a standard
curve or by applying the 2^-∆∆CT method [16].
3.2.4. Quantitative real-time PCR (qRT-PCR) of microRNA 21
To quantify microRNA 21 (miR21) the qRT-PCR-based TaqMan® MicroRNA As-
say hsa-miR-21 from Applied Biosystems was performed. This assay includes
reverse transcription with a miRNA-specific looped primer to convert the mi-
croRNA into cDNA, followed by real-time PCR with cDNA complementary Taq-
Man® probes. The assay was carried out according to the manufacturer’s instruc-
tions. RNA isolated with the Ambion RNA extraction kit was used. As a control,
the RNU43 assay was used.
3.3. Protein biochemistry
3.3.1. Cell lysates for protein gels
Lysis buffer was prepared by adding the following protease inhibitors to IP-
buffer: 50mMNaF, 1mMVanadate, 1mMPMSF (Sigma), 5 µg/ml TLCK (Roche),
16
3. Material and Methods
10 µg/ml TPCK (Biomol), 1 µg/ml leupeptin, 1 µg/ml aprotinin and 10 µg/ml
soybean trypsin inhibitor (all Roche). Cells were harvested and washed in 10 ml
PBS (Invitrogen). Next, the pellet was resuspended in 50 to 200 µl ice cold lysis
buffer to reach a concentration of approximately 1x105 cells / µl . The cell pellet
was resuspended well to achieve good cell lysis and the mixture was immedi-
ately centrifuged for 10 min at 13 000 rpm at 4°C. The supernatant containing
the proteins was transferred into a new vial and the protein concentration was
measured using Bradford assay (Bio-Rad) according to the manufacturer’s in-
structions using a solution of 1 µg/ml BSA as standard. For normalisation, the
samples were diluted in IP-buffer and the appropriate amount of 4 x SDS sample
buffer was added to reach a protein concentration of 100 µg/ 20 µl. The samples
were heated at 95°C for 4 minutes and directly loaded on the acrylamide gel or
stored at -20°C.
IP-buffer 50 mM Tris pH 7,5
150 mM NaCl
5 mM EDTA
5 mM EGTA
1% NP-40
4 x SDS sample
buffer
200 mM Tris- HCl pH 6,8
40% (v/) glycerol
8% (w/v) SDS
brom phenol blue
1,4 M β- mercaptoethanol
3.3.2. SDS-PAGE
20 µl of cell lysate containing 100 µg total protein were loaded on a discontin-
uous polyacrylamide gel consisting of 7% - 15% separating gel (depending on
size of protein of interest) and 5% stacking gel. As weight marker 5 µl PageRuler
Prestained Protein Ladder (Fermentas) were used.
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x % separating gel
30% acrylamide/bisacrylamide x ml
gel buffer 1 7,5 ml
water ad 30 ml
10% APS (Sigma) 300 µl
Temed (Sigma) 30 µl
5% stacking gel
gel buffer 2 10 ml
10% APS (Sigma) 100 µl
Temed (Sigma) 15 µl
The gel was run in running buffer at 60 mA or 90 mA depending on gel size
until the running front reached the gel front. The gels were further analyzed by
western blotting.
gel buffer 1 1,5 M Tris-HCl pH 8,8
0,4% SDS
gel buffer 2 0,125 M Tris-HCl pH 6,8
0,1 % SDS
5 % acrylamide/ bisacrylamide
running buffer 50 mM Tris-HCl pH 8,5
380 mM glycine
7 mM SDS
3.3.3. Western blots
Acrylamide gels were blotted onto a Protran nitrocellulose membrane (Whatman
Schleicher & Schuell) using a semi dry blotting apparatus. The blot was assem-
bled using two filter papers soaked in transfer buffer placed at the anode at the
bottom of the apparatus. The papers were followed by the membrane and the
gel containing the negatively charged proteins. The gel was covered by two more
wet filter papers. To transfer the proteins onto the membrane, the blot was run 1
- 1,5 h at 1 mA/cm2.
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c-Abl and Bcr-Abl blots The nitrocellulose membrane was blocked in blocking
solution 1 for 20 min at least. The c-Abl and Bcr-Abl proteins were detected us-
ing the mouse antibody specifically against Abl (clone 63-21). The antibody was
diluted 1:2000 in blocking solution 1 and incubated for 1 h at room temperature.
After washing the membrane 3 x in PBST the primary antibody was detected
using an Alexa Fluor 680-labeled goat anti-mouse antibody (Invitrogen) diluted
1:7000 in PBST and incubated 1 h at room temperature in the dark. Finally, the
blot was again washed 3 x in PBST. The blot was scanned using the Odyssey
Infrared Imaging System (Li-Cor Biosciences).
Phospho-tyrosine blots The nitrocellulosemembranewas blocked in blocking
solution 3 for 20 min at least. The phosphotyrosine residues were detected using
the mouse antibody specifically against phosphotyrosine (clone 46-10). The an-
tibody was diluted 1:1000 in blocking solution 3 and incubated for 1 h at room
temperature. After washing the membrane 3 x in TBST the primary antibody was
detected using an Alexa Fluor 680-labeled goat anti-mouse antibody (Invitrogen)
diluted 1:7000 in TBST and incubated 1 h at room temperature in the dark. Fi-
nally, the blot was again washed 3 x in TBST. The blot was scanned using the
Odyssey Infrared Imaging System (Li-Cor Biosciences).
p57 Kip2 blots The nitrocellulose membrane was blocked in blocking solution
2 for 40 min at least. The p57 Kip2 protein was detected using the rabbit antibody
(Upstate, #06-556) diluted 1:500 in blocking solution 2 and incubated at 4°C over
night. After washing the membrane 3 x in PBST the primary antibody was de-
tected using an IRDye 800-labeled goat anti-rabbit antibody (Rockland) diluted
1:7000 in PBST and incubated 1 h at room temperature in the dark. Finally, the
blot was again washed 3 x in PBST. The blot was scanned using the Odyssey
Infrared Imaging System (Li-Cor Biosciences).
Grb2 blots The nitrocellulosemembranewas blocked inOdyssey blocking buffer
(Li-Cor Biosciences) for 40 min at least. The Grb2 protein was detected using
a mouse antibody (BD Biosciences #610111) diluted 1:2000 in Odyssey blocking
buffer and incubated for 1 h at room temperature. After washing the membrane
3 x in PBST the primary antibody was detected using an Alexa Fluor 680-labeled
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goat anti-mouse antibody (Invitrogen) diluted 1:7000 in PBST and incubated 1
h at room temperature in the dark. Finally, the blot was again washed 3 x in
PBST. The blot was scanned using the Odyssey Infrared Imaging System (Li-Cor
Biosciences).
Cbl, Sts1, Ship2 blots The nitrocellulose membrane was blocked in Odyssey
blocking buffer for 40min at least. The proteins were detected using the following
primary antibodies: α-Cbl clone 33-77 diluted 1:1000, α-Sts1 clone 34-11 diluted
1:500 and α-Ship2 (provided by Wisniewski1) diluted 1:1000 in Odyssey blocking
buffer and incubated for 1 h at room temperature. After washing the membrane
3 x in PBST the primary antibody was detected using an IRDye 800-labeled goat
anti-rabbit antibody (Rockland) diluted 1:7000 in PBST and incubated 1 h at room
temperature in the dark. Finally, the blot was again washed 3 x in PBST. The blot
was scanned using the Odyssey Infrared Imaging System (Li-Cor Biosciences).
Shc blots The nitrocellulose membrane was blocked in blocking solution 2 for
40 min at least. The Shc protein was detected using a mouse antibody (BD Bio-
sciences, #610878) diluted 1:500 in blocking solution 2 and incubated for 1 h at
room temperature. After washing the membrane 3 x in PBST the primary anti-
body was detected using an Alexa Fluor 680-labeled goat anti-mouse antibody
(Invitrogen) diluted 1:7000 in PBST and incubated 1 h at room temperature in the
dark. Finally, the blot was again washed 3 x in PBST. The blot was scanned using
the Odyssey Infrared Imaging System (Li-Cor Biosciences).
PBST 0,1% Tween-20 (Sigma)
in PBS
TBST 0,1% Tween-20 (Sigma)
in TBS
blocking solution 1 3% (w/v) BSA
in PBST
blocking solution 2 5% blotting Grade Blocker Non-Fat Dry Milk
in PBST
1Wisniewski et al., Blood 93 (8), 1999
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blocking solution 3 5% blotting Grade Blocker Non-Fat Dry Milk
in TBST
transfer buffer 2,5 mM Tris
15 mM glycine
10% (v/v) methanol
3.3.4. IL8 ELISA
The Interleukin-8 ELISA kit was bought from BD Biosciences and used according
to the manufacturer’s instructions. In brief, a 96-well plate was coated with Coat-
ing antibody diluted 1:250 in Coating buffer, sealed and incubated over night at
4°C. The next day, the plate was washed 3x with Washing buffer (300 µl/well)
and blocked with 200 µl/well Assay diluent. The plate was again sealed and
incubated for 1 h at room temperature. After another washing step ( 3x with
Washing buffer, 300 µl/well), 100 µl of each standard, sample and control were
pipetted into the appropriate wells. Each standard, sample and control was an-
alyzed in duplicates or triplicates. The standard was prepared using the stock
solution and diluted in Assay diluent. If necessary, the samples were diluted be-
tween 1:2 and 1:5 in assay diluent as well. The sealed plate was incubated at
room temperature for 2 h. Next, the plate was washed again as before, but with
5 washing repeats. Then, 100 µl prepared Working detector were added to each
well. Again, the plate was sealed and incubated 1 h at room temperature. The
last washing step was repeated 7 times, the wells were soaked in Washing buffer
for 30 seconds for each wash. Then 100 µl of Substrate solution (R&D Systems)
were pipetted into each well. The plate was incubated up to 30 minutes in the
dark without a sealer. The reaction was stopped by adding 50 µl stop solution
(2 N H2SO4). The absorbance at 450 nm was immediately measured using a mi-
croplate reader (Spectra Max M5, Molecular Devices).
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Coating buffer 0.1 M Sodium Carbonate pH 9.5
8.4 g NaHCO3
3.56 g Na2CO3
Washing buffer 0.05% Tween-20 (Sigma)
in PBS
Assay diluent 10% FCS (Invitrogen)
in PBS
Working detector 1:250 Detection Antibody
1:250 SAv-HRP reagent
in Assay diluent
3.3.5. Flow cytometry analysis of CD69 surface expression
Cells were harvested and washed in FACS buffer. Approximately 1x105 cells
were resuspended in FACS buffer. The PE-labelled mouse monoclonal antibody
against human CD69 (#MHCD6904, Caltag/Invitrogen) was added 1:20 to the
cell suspension and incubated for 20 minutes on ice in the dark. Then, the cells
were washed twice in FACS buffer and resuspended in 30 µl FACS buffer. 5 µl
7’AAD (eBioscience) were added to stain dead cells. The cells were analyzed
by flow cytometry using the BD FACSCaliburTM system. 7’AAD negative cells
were gated to compare CD69 expression on non-treated and drug-treated cells.
Analysis was performed using the BD CellQuest Pro software.
FACS buffer 3% BSA
0.05% NaN3
in PBS
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4.1. Marker for drug-dependent Bcr-Abl inhibition
4.1.1. DNA-microarray - candidate identification
The first approach for finding molecular markers for Bcr-Abl activity was a mi-
croarray experiment. The expression pattern of K562 cells grown under nor-
mal conditions was compared to the expression pattern of K562 cells, that were
treated with 100 nM Dasatinib for 3 h. For this experiment the GeneChip ® Hu-
man Genome U133 Plus 2.0 Array was used. The statistical analysis of the ob-
tained data set revealed, that more than 1600 genes could be determined as dif-
ferentially expressed after drug treatment compared to the non-treated control
cells. The majority was down-regulated and only 18% of all regulated genes
were up-regulated after the treatment. The divergence ranged from 0.01-fold
change (most prominently down-regulated gene upon drug treatment) to 5.51-
fold change (most prominently up-regulated gene).
From this large dataset a selection of genes was chosen to be further investigated.
Selection of candidates was performed under the aspects of degree of expression
change and properties of the protein. Preferentially, the protein should be either
localized on the cell surface or secreted by the cell to be fast and easily detectable.
Finally, a list of 33 genes was generated, 26 of them down-regulated after drug
treatment, 7 up-regulated. Figure 4.1 shows a scheme of a cell, illustrating the cel-
lular localization of all the candidates and their relation to the Bcr-Abl machinery
as far as this is known [2, 17].
The candidate proteins show very diverse properties concerning cellular local-
ization and function. The list contains secreted and membrane spanning proteins
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Figure 4.1: Scheme of relation of marker candidates to Bcr-Abl
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as well as cytoplasmic or nuclear located proteins and proteins embedded in the
membrane of the endoplasmatic reticulum or mitochondria. Some of the candi-
dates can be directly linked to Bcr-Abl. They are known to bind and eventually
influence Bcr-Abl itself or its binding partners (e.g. SOCS1, SOCS3, SPRY4). For
another subset of candidates no direct link to Bcr-Abl is known (e.g. IL10RA,
CD69, IFIT1). The list also contains proteins that are very poorly described at all
(e.g. TMEM 58, ERMAP, AMIGO2) [17].
Hakansson et al. [18] transfected the Bcr-Abl oncogene to U937 cells and com-
pared the expression pattern of parental and Bcr-Abl transfected cells by microar-
ray analysis. They identified 61 up-regulated genes in the Bcr-Abl positive U937
cells. Interestingly, the list of the proteins they identified as up-regulated after
Bcr-Abl induction partly overlaps with our list of down-regulated genes after
Bcr-Abl inhibition (e.g. CISH and PIM1). This provides strong evidence, that the
oncogene itself influences the expression regulation machinery of these proteins.
Paradoxically, they reported IFIT1 to be up-regulated in Bcr-Abl transfected U937
cells, we found IFIT1 to be up-regulated K562 cells after drug-dependent Bcr-Abl
inhibition.
4.1.2. Confirmation of the microarray results on RNA level
using quantitative real-time PCR
To confirm the microarray data on RNA level quantitative real-time PCR (qRT-
PCR) was performed. The investigation was extended by not only comparing
non-treated K562 cells to Dasatinib-treated cells, but also to Nilotinib-treated
cells. Dasatinib was again used at a concentration of 100 nM as for the microarray
experiments, Nilotinib was used at a concentration of 1 µM . At these concen-
trations, tyrosine phosphorylation could no longer be detected in K562 cells by
phosphotyrosine specific western blotting.
Figure 4.2 shows the comparison of the results from the microarray experiments
and the qRT-PCR experiments (see appendix, table A.4 for exact values).
Changes in the expression pattern of K562 cells upon treatment with Bcr-Abl in-
hibitor drugs were investigated on RNA level via two different methods, mi-
croarray and qRT-PCR. For most of the candidates, the expression changes from
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Figure 4.2: Comparison of microarray results and qRT-PCR results for drug dependent
regulation of candidate expression
both methods match very well (CD69, IL10RA, CISH, PHLDA1, GDF15, MAFF,
SOCS1, SLC2A3, HHEX, BHLHB2, BCL2L1, ATF3, STC2, AMIGO2, PIM1, ERMAP,
FAM46B, p57Kip2, CYP3A5). For some others (EGR1, IL8, SPRY4, APOL4, CHAC1,
SOCS3, TEMEM56, IFIT1) the results from the qRT-PCR did not correlate that
well with those of the microarray. However, the tendency of regulation could be
confirmed for nearly all the candidate genes. HEC2W, MYC, ETV5, ITPR1 and
LGR4 could not be successfully analyzed by qRT-PCR.
Treatment with Dasatinib and Nilotinib led to very similar regulation effects for
all the candidates. Although Dasatinib has a broad target spectrum and inhibits
a number of important kinases and Nilotinib is a very specific inhibitor for Bcr-
Abl, both drugs have the same influence on the expression of candidate genes.
As there is very little overlap in the targets of Dasatinib and Nilotinib [19], these
results strongly indicate, that the changes in the expression levels of the candidate
genes are very likely to be regulated via Bcr-Abl and not via some other targets
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of the drugs.
To assure, that the expression change of the candidates is an effect of specific
Bcr-Abl inhibition by both drugs, we performed the same qRT-PCR experiments
using U937 as a control cell line (only for a subset of candidates). U937 cells do not
express the Bcr-Abl fusion gene. Therefore the drug treatment should not affect
the expression of the candidate genes. U937 cells were cultivated at the same
concentrations of Dasatinib or Nilotinib for 3 h. Again, the expression level of the
candidate genes in non-treated U937 cells was compared to the levels in treated
cells (see figure 4.3, a table showing the exact data is provided in the appendix,
table A.4).
Figure 4.3: qRT-PCR results of U937 cells vs. K562 cells
Drug treatment has only a small effect on the expression level of the majority of
tested candidate genes in U937 cells. These results again provide strong evidence,
that the regulation of most of the candidate genes is a consequence of Bcr-Abl in-
hibition. Significantly high changes were obtained IL8. For this candidates, drug
treatment has an opposite effect in U937 than in K562 cells. Prominent changes in
the expression after drug treatment of U937 cells could also be detected for EGR1
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and CISH. However, the effect is much higher in K562 cells. The candidate genes
TMEM and CYP3A5 are regulated in the same range in K562 cells as well as in
U937 cells. They must be suspected to be regulated via another target protein
of Dasatinib and Nilotinib and are therefore excluded from the list of possible
markers for drug-dependent inhibition of Bcr-Abl.
4.1.2.1. MicroRNA 21
MicroRNA 21 (miR21) was also detected to be down-regulated upon drug treat-
ment in the microarray experiment (0,28-fold induction). For investigation of
miRNAs with qRT-PCR special methods need to be used for RNA preparation
and reverse transcription. Using the Ambion miRVana miRNA Isolation Kit and
the TaqMan MicroRNA real-time PCR Assay from Applied Biosystems, down-
regulation of miR21 (0,55-fold change) could be detected upon drug treatment in
K562 cells whereas the treatment causes slight up-regulation in U937 cells (1,3-
fold change) (see figure 4.4).
Figure 4.4: miR21 expression in K562 cells and U937 cells
MicroRNA21 expression seems to be influenced by Bcr-Abl activity. However,
miRNA detection is expensive and time-consuming, therefore miR21 can not be
used as diagnostic marker.
4.1.3. Bcr-Abl knock-down in K562 cell line
If the Bcr-Abl fusion protein is responsible for the regulation of the candidate
genes, knock-down of Bcr-Abl should have the same influence on the expression
of the candidates as inhibition of Bcr-Abl by drugs.
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A protocol for transient siRNA transfection of K562 cells was successfully estab-
lished in the laboratory. Bcr-Abl knock-down in K562 cells was achieved using
an siRNA homologous to the breakpoint region of the Bcr-Abl p210 gene (BAF 7).
This siRNA leads to a knock-down of Bcr-Abl but it does not target c-Abl or Bcr.
As a control, a missmatch siRNA with 3 altered bases was used (BAF 8) [15].
A knock-down of Bcr-Abl to 30% expression could be achieved (not shown). In
contrast to the cells that were transfected with the control siRNA, the Bcr-Abl
knock-down cells stopped proliferating and died after 48 h (see figure 4.5).
It was not possible to rescue the cells by providing a growth factor cytomix con-
taining Interleukin-3 (IL-3), Interleukin-6 (IL-6), Stem cell factor (SCF) and granu-
locyte-macrophage colony-stimulating factor (GM-CSF), each of them at a con-
centration of 1 ng/ml. Growth and viability of Bcr-Abl knock-down cells did not
recover when cultivating the cells in cytomix. The cells do not respond to the
growth factors. It is possible, that K562 cells do not express sufficient receptors
for these growth factors as the survival signal of Bcr-Abl is normally sufficient for
the cells to grow. The K562 cells seem to be completely oncogene addicted. The
cells are dependent on the growth and survival signals induced by Bcr-Abl.
4.1.4. Investigation of candidate p57 Kip2 on protein level
On RNA level the potent tumor supressor gene p57 Kip2 was up-regulated upon
drug treatment. As long as the Bcr-Abl oncogene is active, this negative regulator
of proliferation is kept at low level. The microarray data as well as the qRT-PCR
results for Dasatinib and Nilotinib treatment showed a 4-fold up-regulation of
the mRNA after 3 hour drug treatment. For the investigation on protein level,
K562 cells were treated with the drugs for 3 to 24 hours. As shown in figure 4.6,
western blot analysis did not show up-regulation of the protein on any time point
after drug treatment.
Although the mRNA level has increased to the 4-fold after 3 hours of drug treat-
ment, the amount of the protein remains unchanged. It is not possible to examine
p57 Kip2 levels after extended drug treatment as K562 cells die due to the inhi-
bition of the oncogene. p57 Kip2 can not be used as marker for drug-dependent
Bcr-Abl inhibition on protein level.
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(a)
Figure 4.5: Growth and viability of Bcr-Abl knock down cells
BAF8: missmatch siRNA, BAF7: siBcr-Abl, st: single transfection,
dt: double transfection (second transfection after 24 h)
4.1.5. Investigation of candidate CD69 on protein level
The second candidate investigated on protein level was CD69. As a surface re-
ceptor protein, CD69 would be a suitable marker for Bcr-Abl activity as it can
easily be detected by flow cytometry.
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Figure 4.6: Quantification of p57 Kip2 in K562 cells after drug treatment by western
blotting
On RNA level, CD69 was down-regulated to around 3% expression (= 40-fold
down-regulation) upon drug treatment of K562 cells, whereas no significant ef-
fect could be detected in U937 cells. Expression on protein level was investigated
by flow cytometry analysis after 16 h of drug treatment. The cells were stained
for CD69 and treated with 7’AAD to distinguish between living and dead cells.
CD69 expression was examined on K562 cells as well as on U937 cells as a con-
trol. Figure 4.7(a) shows, that down-regulation of CD69 in K562 cells upon drug
treatment could be detected by flow cytometry analysis. A reduction from 30%
to 10% CD69-positive K562 cells could be observed. The treatment did not af-
fect CD69 expression on U937 cells. Independently of drug treatment, U937 cells
always stay 100% positive for CD69 (see figure 4.7(b)). The fact, that the CD69
signal is lower in untreated K562 cells than in untreated U937 cells may be cell
type specific, K562 cells may generally express less CD69 protein on their surface.
The autofluorescence of non-stained K562 cells changes upon drug-treatment, the
peak of Dasatinib- and Nilotinib-treated, non-stained cells is slightly shifted to
the left in comparison to non-treated, non-stained cells (fig. 4.7(a)). Inhibition
of Bcr-Abl and the subsequent changes in expression pattern and composition of
proteinsmay be sufficient to alter the autofluorescence of the cell. Similar changes
in autofluorescence can not be observed in U937 cells, the drugs affect the cells to
a smaller extent (fig. 4.7(b)).
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(a) CD 69 in K562 cells
(b) CD 69 in U937 cells
Figure 4.7: CD69 expression in K562 cells and U937 cells after 16 h drug treatment
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4.1.6. Investigation of candidate Interleukin-8 on protein level
Interleukin-8 (IL8) is a secreted cytokine and plays an important role inmediating
inflammatory response. IL8 would be an appropriate marker for drug response
as it is easily and rapidly detectable in supernatants as well as in blood serum by
ELISA.
4.1.6.1. Interleukin-8 expression in K562 cells
For the analysis of the Bcr-Abl dependent IL8 expression, K562 cells and U937
cells were treated with either Dasatinib or Nilotinib for 3 h to 24 h and the super-
natants were analysed by ELISA.
The results show, that non-treated K562 cells express about 4,5 times more IL8
than non-treated U937 cells. This can be due to Bcr-Abl expression, that is not
present in the U937 control. K562 cells react to Dasatinib and Nilotinib treatment
with reduction of IL8 secretion. Figure 4.8 shows the IL8 levels in the super-
natants normalized to 1 x106 cells/ml at timepoint of harvest (data see appendix,
table A.6).
Figure 4.8: IL8 secretion upon drug treatment in K562 and U937 cells
After 3 h of drug treatment, the IL8 levels are still the same in non-treated and
treated K562 cells. After 9 h treatment, the IL8 levels are reduced to half amount
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in treated K562 cells. After 24 h this difference is even more prominent. Drug
treatment does hardly affect the U937 cells, the IL8 levels remain the same for
treated and non-treated cells at every time point.
4.1.6.2. Interleukin-8 expression in UT7 cell line
Dasatinib sensitivity of UT7 p210 UT7 cell line (UT7 par) is a GM-CSF depen-
dent cell line. Stable transfection of UT7 cells with the Bcr-Abl oncogene (UT7
p210) renders them GM-CSF independent. The Bcr-Abl oncogene induces a pro-
liferation signal in the UT7 cells, which replaces the signal of GM-CSF. Growth of
UT7 par (in medium containing GM-CSF) is not affected by Dasatinib, whereas
UT7 p210 growing under GM-CSF starvation die at a concentration of 100 nM
Dasatinib (see figure 4.9). It was not possible to rescue Dasatinib treated UT7
p210 cells by providing GM-CSF (not shown).
Figure 4.9: Growth of UT7 par and UT7 p210 cells in increasing concentration of Dasa-
tinib
Regulation of IL8 secretion upon drug treatment UT7 par andUT7 p210 cells
were treated with the same concentrations of Dasatinib (100 nM) and Nilotinib (1
µM) as K562 andU937 cells and the IL8 levels in supernatant were again analyzed
by ELISA. In the UT7 p210 cells the IL8 secretion level is significantly higher
compared to UT7 par. Figure 4.10 shows, that UT7 p210 cells secrete 3 times more
IL8 than the parental cells. Drug treatment does not influence IL8 expression in
UT7 par cells, whereas in UT7 p210 cells IL8 levels are reduced to 30% after 3 h
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of drug treatment. The effect of drug treatment is even more prominent after 16
h and 24 h. Bcr-Abl inhibition in UT7 p210 cells leads to down-regulation of IL8
secretion to similar amounts as the parental cell line UT7 par (exact data values
provided in appendix, table A.7).
Figure 4.10: IL8 secretion upon drug treatment of UT7 par and UT7 p210 cells
4.1.6.3. IL8 in CML
Bcr-Abl dependent expression of IL8 was also tested in blood serum from 4 CML
patients. In preliminary experiments, the IL8 expression in serum from newly
diagnosed CML patients was compared to their serum IL8 levels during drug
therapy. The CML patients, whose samples were used for the study were on
Imatinib therapy, as this is the first line therapy for the disease. Dasatinib treated
patients are very rare, Nilotinib treatment is only permitted since November 2007
in Austria. As controls, serum samples from 2 healthy donors were also tested.
Results are shown in figure 4.11 (see appendix, table A.8 for exact data values).
Around 10 pg/ml of IL8 could be detected in serum samples of healthy donors.
This value was taken as a threshold for analysis of IL8 levels in patient samples.
All CML patients showed elevated IL8 levels at time of diagnosis in comparison
to the healthy donors. IL8 levels CML patients 1 and 4 normalize already 1 month
after Imatinib therapy and stay down after 3 months. Patient 2 shows normaliza-
tion of IL8 after 3 months, but the levels are again up-regulated after 12 months
therapy. This patient does not show complete cytogenetic response even after
12 months Imatinib therapy. Serum IL8 levels of patient 3 also normalize after
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Figure 4.11: IL8 levels in serum from CML patients (* compete cytogenetic response)
already 1 month. After 3 moths of therapy, IL8 secretion is again increased, but
re-normalized after 24 months when complete cytogenetic response was reached.
These results support the therory, that Bcr-Abl leads to an increase of IL8 in the
serum of CML patients. Still, these are preliminary data and the IL8 levels were
not normalized to the white blood cell counts.
4.2. Role of Bcr-Abl core interactors in Bcr-Abl
signaling
Bcr-Abl is a very potent oncogene, it is sufficient to induce cancerous survival,
growth and proliferation signals in cells. Bcr-Abl closely binds and interacts with
a variety of proteins that are known to be closely linked to important signaling
pathways in the cell.
Several direct and indirect interaction partners of Bcr-Abl have already been iden-
tified by large-scale IP. Tandem affinity purification (TAP) using TAP-tagged Bcr-
Abl as bait and subsequent mass spectrometry analysis of the purified proteins
was performed previously in the lab. The list of proteins identified overlaps
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very well with known interactors, some unknown binding partners could also
be found. According to the pulldown experiment, the most abundant interactors
of Bcr-Abl were chosen to be examined in particular (Brehme, M., Hantschel, O.,
not published):
• Grb2
• CrkII
• Cbl
• Shc
• Ship2
• Sts1
• p85 α
• p85 β
It is not clear until now, which interactions are crucial for the Bcr-Abl signaling.
By knocking down each of these core interactor proteins critical signal mediators
of Bcr-Abl should be identified.
4.2.1. Knock-down of Bcr-Abl core interactors in K562 cells
Knock-downswere achieved by transfecting K562 cells with Dharmacon SMART-
pool siRNAs using HiPerFect transfection reagent. Each core interactor protein
could successfully be targeted and its expression could be reduced to 20% at least
(see figure 4.12 and table 4.1).
Growth and viability of K562 cells were monitored using the CASY Counter sys-
tem. Table 4.1 shows the knock-down efficiencies of the target proteins and the
viability of the cells. It was not possible to detect a growth reduction after core
interactor knock-down. Cells died after knock-down of Bcr-Abl and c-Abl.
The knock-down samples were also tested for tyrosine phosphorylation by west-
ern blot analysis using a specific anti-phosphotyrosine antibody. Figure 4.13
shows, that tyrosine phosphorylation was not affected by any knock-down. The
tyrosine phosphorylation of the cell, which is fully induced by Bcr-Abl, is not
significantly changed upon knock-down of any Bcr-Abl core interactor.
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Figure 4.12: Knock-down efficiency of core interactors in K562 cells determined by west-
ern blotting
The missing band in the lane where the lysate of the Ship2 knock-down was ap-
plied is Ship2 itself, the signal is lost because of elimination of the protein. The
upcoming band in lane 3, where the control knock-down was loaded and in the
last lane could not be identified.
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Table 4.1: Knock-down efficiency of core interactors in K562 cells determined by qRT-
PCR and western blotting and viability of knock-down cells
core
interactor
Knock-down
efficiency
determined by
qRT-PCR (%)
Knock-down
efficiency
determined by
western blot
(%)
viability (%)
Bcr-Abl 89 60
c-Abl 85 60
Grb2 87 89 90
CrkII 80 90
Cbl 76 90
Sts1 75 90
Shc 90 80 90
Ship2 81 90
p85α 85 90
p85β 97 90
Figure 4.13: α-phospho-tyrosine blot of K562 knock-down cells
4.2.2. Knock-down of Bcr-Abl core interactors in UT7 p210
cells
Knock-down of core interactors was also performed in UT7 p210 cells. Trans-
fection of Dharmacon SMARTpool siRNA into UT7 p210 cells using the Amaxa
electroporation system was sucessfully estblished. Figure 4.14 shows the knock-
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down efficiencies for all proteins where knock-down was performed. Growth
of the cells was only monitored by eye, an effect of a knock-down could not be
observed.
Figure 4.14: Knock-down efficiency determined by western blotting
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5.1. Identification of markers for Bcr-Abl activity
The constitutively active tyrosine kinase Bcr-Abl tightly interacts with a variety
of proteins and activates a broad range of important cellular signaling pathways.
The transcription factors at the end of these signaling cascades influence the reg-
ulation of numerous genes. The Bcr-Abl signaling not only regulates the ex-
pression of genes required for the survival and growth signaling, it also leads to
prominent up- or down-regulation of other target proteins that do not necessar-
ily contribute to the cancerous properties of Bcr-Abl positive cells. When Bcr-Abl
is inhibited by treatment of the cells with specific drugs, the levels of Bcr-Abl
dependent genes should come back to a normal expression level.
Up to know, the effect of drug therapy in patients can only be determined via
white blood cell count or examination of Bcr-Abl positive cell clones in serum or
bone marrow by FISH or cytogenetic analysis using RT-PCR. It takes around one
month until the effects of therapy are detectable. For CML patients and doctors
it would be very convenient if the duration until the result of therapy can be
determined was shortened. This would allow a faster adjustment of therapy for
every single patient.
5.1.1. Candidate investigation on RNA level
Using amicroarray, more than 1600 genes turned out to be differentially regulated
in K562 cells with inhibited Bcr-Abl compared to cells with an active oncogene.
For 27 of these candidates a Bcr-Abl dependent regulation could be confirmed on
RNA level by qRT-PCR. Two proteins, Interleukin-8 and CD69, could be shown
to be Bcr-Abl dependently regulated on protein level in cell lines.
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The candidate genes were shown to be similarly regulated on RNA level after
treatment with Dasatinib or Nilotinib. Although Dasatinib is much less specific
than Nilotinib, both drugs influence Bcr-Abl positive cells in the same manner.
Including the finding, that drug treatment has only minor effects on Bcr-Abl neg-
ative cells, it is very likely, that these genes can be used as potent markers for
Bcr-Abl activity.
This list of genes consists of very interesting candidates, including Egr1, CD69,
IL10RA, Pim1, IFIT1, SOCS1, SOCS3, p57Kip2 and others that have been previ-
ously linked to different types of cancer or even to Bcr-Abl signaling.
5.1.1.1. Egr1
Surprisingly, the most prominently down-regulated gene upon inhibition of Bcr-
Abl was Egr1, Early growth response protein 1. This zinc-finger transcription
factor is supposed to be a tumor suppressor gene, its expression was reported to
be reduced in many different types of tumors [20]. Fukada and Tonkast reported
in 2001 that Bcr-Abl down-regulates Egr1 expression [21]. This is in contrast to
our data, where drug-dependent Bcr-Abl inhibition leads to down-regulation of
Egr1.
Stuart et al. published in 2005, that Egr1 expression is induced by the active c-
Abl kinase [22]. This is in line with our results, Bcr-Abl and c-Abl could similarly
affect Egr1 expression.
5.1.1.2. Pim-kinases and SOCS proteins
Pim1 and Pim2 expression was reduced to 17% and 44% in the microarray ex-
periment respectively. Pim1 down-regulation was validated by qRT-PCR. Down-
regulation of Pim1 after drug treatment matches very well with the literature.
Pim-kinases were reported to act as proto-oncogenes. The phosphorylation tar-
gets of the Pim1 and its close relatives Pim2 and Pim3 are involved in the reg-
ulation of cell cycle and apoptosis. Amongst others, Pim-kinases act on Bcr-Xs,
Cdc25A and NFATc and drives the cell towards cell cycle progression. Over-
expression and mutations have been found in a number of different tumors in-
cluding lymphomas, prostate cancer, oral tumors and also CML. Pim1 expression
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is induced by Bcr-Abl activated STAT5 [23]. Chen et al. recently reported that
Pim1 and Pim2 are down-regulated in Imatinib treated v-Abl positive cells. They
also showed higher SOCS1 turnover and subsequent lower SOCS1 levels in Pim1
and Pim2 deficient mice. Furthermore, the SOCS proteins have been shown to
be substrates of Pim1. Phosphorylation of SOCS1 and SOCS3 lead to the inhibi-
tion of these proteins which in turn blocks their negative influence on the JAK -
STAT pathway [23, 24]. In the microarray experiment SOCS1 and SOCS3 were
down-regulated to 14% and 19% respectively after drug treatment. SOCS2 was
reduced to 33%. Down-regulation of SOCS1 and SOCS3 after cell treatment with
Dasatinib and Nilotinib could be confirmed by qRT-PCR. Further investigation
of the Pim-kinases and the SOCS-Proteins and their eligibility as marker proteins
should be performed.
5.1.1.3. MicroRNA 21
MicroRNA 21 was shown to be down-regulated upon Bcr-Abl inhibition. This
microRNA has already been extensively studied. It has been reported to be over-
expressed in tumor tissues and it down-regulates tumor suppressor genes like
TPM1 and PTEN [25, 26]. This is in line with our results. If miR21 up-regulation
is a consequence of Bcr-Abl activity, this microRNA could play an important role
in the development of CML.
5.1.2. Candidate investigation on protein level
Three candidates have been further studied on protein level.
5.1.2.1. p57 Kip2
The p57 Kip2 protein is also called Cyclin-dependent kinase inhibitor 1C. Located
to the nucleus, it is a binding inhibitor of several G1 cyclin/Cdk complexes and
acts a negative regulator of proliferation. It is suspected to be a potent tumor
suppressor gene and has already been related to the Beckwith-Wiedemann syn-
drome and sporadic cancers [27]. These properties make it a potent marker for
Bcr-Abl activity.
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p57 Kip2 was shown to be 3,5-fold up-regulated on RNA level. On protein level,
it was not possible to observe up-regulation after treatment with Dasatinib or
Nilotinib for 3 to 24 h. It may be a stable protein with a very low turnover rate.
The translation of mRNA into protein may occur very slowly, that up-regulation
is not detectable even after 24 h of drug treatment.
This protein is not a suitable marker for Bcr-Abl activity.
5.1.2.2. Regulation of CD69
The second candidate, that was studied on protein level is CD69. This type II in-
tegral membrane protein appears to be the earliest inducible surface-glycoprotein
during lymphoid activation in T- and B-cells. Upon several stimuli it is inducible
in T-cells, B-cells, neutrophils and eosinophils. Several other cell types of the im-
mune system, including bone marrow myeloid precursors, constitutively express
CD69. CD69 acts as a signal transduction molecule and is able to induce expres-
sion of c-MYC and c-FOS. It is therefore supposed to play a role in lymphocytic
proliferation. Binding partners and exact function remain unrevealed [28, 29].
CD69 was down-regulated to 2% expression on RNA level upon drug treatment.
Flow cytometry analysis of drug treated K562 cells showed that the surface ex-
pression of CD69 is down-regulated to 1/3 upon 16 h treatment with Dasatinib
or Nilotinib while no effect could be observed for U937 cells.
Other cell lines or primary cells were not investigated yet. Testing UT7 p210 cells
for down-regulation of the protein after drug treatment turned out to be difficult.
Induction of Bcr-Abl leads to a modification of size and shape in UT7 cells. UT7
p210 cells again adopt the structure of UT7 par cells. This alteration leads to
problems in gating the comparable populations in flow cytometry analysis.
Flow cytometry analysis of primary cells would maybe require a prior sorting of
cells and certainly would have to include multiple stainings to distinguish be-
tween different cell types.
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5.1.2.3. Regulation of Interleukin-8
The cytokine IL8 is expressed by various cell types including monocytes in re-
sponse to inflammatory stimuli (IL-1, tumor necrosis factor) and functions as
chemoattractant for granulocytes. It is also a potent angiogenic factor [1, 30].
IL8 transcription could be shown to be down-regulated in Dasatinib and Nilo-
tinib treated K562 cells to 2 - 10% after 3 h of drug treatment. On protein level,
IL8 was also observed to be down-regulated in K562 cells as well as in UT7 p210
cells upon inhibition of Bcr-Abl with Dasatinib and Nilotinib over a period of 24
h. This experimental setup only gives information about the amount of secreted
IL8, values for the intracellular IL8 protein levels can not be determined using
ELISA. Due to the results on RNA level it is very likely, that not only IL8 secretion
but also translation is reduced when Bcr-Abl in inhibited. The drug treatment did
not influence the secretion of IL8 in the control cell lines U937 and UT7 par.
Preliminary data could also be achieved for changes of IL8 levels in serum sam-
ples of CML patients after onset of Imatinib therapy. It seems as if Imatinib ther-
apy has a similar effect on IL8 secretion in CML patients as Dasatinib and Nilo-
tinib have in cell lines. Elevated IL8 transcription and secretion from myeloblasts
derived from CD34+ cells of CML patients have already been reported, the effect
of drug therapy on the cells was not tested [31].
5.2. Role of Bcr-Abl core interactors in Bcr-Abl
signaling
So far, the signaling of Bcr-Abl is only poorly resolved. Direct interactors of Bcr-
Abl are known, but it is not sure if the list is complete. Bcr-Abl either phosphory-
lates its direct interactors or the binding partners of the core interactors which in
turn leads to the activation of a number of important signaling pathways in the
cell and to the alteration of the expression pattern of the cell, influencing the cell
cycle in an anti-apoptotic and proliferation inducing manner. In the presence of
Bcr-Abl in a cell, a number of important signal transduction cascades are active.
One pathway may be targeted by more than one core interactor of Bcr-Abl. It is
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not clear, which interaction partners of Bcr-Abl are crucial and necessary for the
cancerous signaling.
Selective inhibition of close downstream targets of Bcr-Abl could improve treat-
ment of CML and permit better therapeutic achievements in case of drug insen-
sitive Bcr-Abl mutations, but requires detailed information about mechanisms of
Bcr-Abl signaling.
By performing single knock-down experiments of known Bcr-Abl core interactor
proteins in Bcr-Abl positive cells and analysis of cell growth, critical signaling
partners of Bcr-Abl should have been identified. Experiments were performed in
K562 cells and UT7 p210 cells, knock-downs efficiencies were between 60% and
90%. Complete elimination of the target proteins was not achieved.
Growth impairment could not be observed for any knock-down. Several reasons
may explain these results. The reduction of the copy number may not be suffi-
cient to impair or decrease the signal strength. The remaining copies of the target
protein may be enough for sufficient interaction and maintaining the Bcr-Abl sig-
nal transduction. Complete removal of the protein would then be necessary to
provoke a phenotypic effect.
Another possible explanation is, that the elimination of one single core interactor
protein does not impair Bcr-Abl signaling. Other activation routes may overcome
the missing signal to keep the critical signaling cascades active. In Bcr-Abl pos-
itive cells, various important signaling pathways are active and the disruption
of one single activation mechanism may not be enough to reduce the growth and
proliferation signal. This could be resolved by performing multiple knock-downs
in the cell, but the number of possible combinations is high.
An additional possibility is, that the partial elimination of one core interactor only
causes a minor effect in cell proliferation which was not detected by the methods
used for the read-out. Growth impairment was only determined by cell counting.
More sensitive read-out methods may be necessary to detect the effect. For the
knock-down of the core interactors Sts-1 and Cbl an XTT cell proliferation assay
was performed but influences on cell growth could not be observed.
Some of the core interactors are suspected to influence Bcr-Abl in a positive man-
ner. The interaction between Bcr-Abl and the core interactor causes forwarding
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or amplification of the signal. Some components of the core complex are sus-
pected to be rather negative regulators of the Bcr-Abl signal. The phophatase
Sts1, the E3 ubiquitin ligase Cbl and the inositol phosphatase Ship2 are very likely
to negatively influence the Bcr-Abl signaling by interfering with the Bcr-Abl sig-
nal transducers or inactivation of those. If this is the case, knock-down of the
proteins should boost the proliferation of the cells, which could not be observed
either.
5.2.1. Suggestions for continuation of the project
Interleukin-8 is planed to be further investigated in serum from CML patients.
Statistically significant statements absolutely require expansion of the study. Be-
sides testing a higher number of serum samples from CML patients, also Ph+
ALL patient material will be analyzed. As controls, the study will include serum
samples from patients suffering from other myeloproliferative diseases, samples
from patients suffering from other types of leukemia and of course from healthy
donors. IL8 can rise quickly due to a minor infection, as it is an important medi-
ator of inflammation. Therefore, it is important to know the state of health of the
donors at the timepoint of blood collection.
Further studies on CD69 in other cell lines and in primary bone marrow cells
would be necessary to proof the availability of CD69 as marker for Bcr-Abl activ-
ity in vivo.
Last but not least, many other possible candidates investigated on RNA level
should definitely be studied on protein level. This could not only make them
available as marker proteins for Bcr-Abl activity, but it could also help to re-
veal and understand the signaling network of Bcr-Abl. Interesting candidates
are Pim1 and the SOCS proteins. Regulation of miR21 and its role in the develop-
ment of CML could also be extensively studied. Investigation of similar mode of
action as shown for other types of cancer could help to elucidate another mecha-
nism of Bcr-Abl action.
The other part of the project could be pursued by improving the knock-down ef-
ficiencies and performance of cell proliferation assays. More sensitive read-out
methods for proliferation may be necessary to detect the phenotype of core in-
teractor knock-down. Analysis of combination of knock-down of multiple core
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interactors could reveal which core interactors are involved in the same signal-
ing pathways. One could also test, if the knock-down of the Bcr-Abl interactors
influences the expression of the activity markers investigated in the first part of
this work.
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A. Appendix - Supplementary
figures
Table A.1: siRNA constructs
BAF7 (sequence specific to Bcr-Abl breakpoint region)
sense: 5‘-CAGAGUUCAA|AAGCCCUUCAGdTdT-3‘
antisense: 3‘-dTdTGUCUCAAGUU|UUCGGGAAGUC-5‘
BAF8 (missmatch control)
sense: 5’-CAGUGUUCAU|AAGCCGUUCAGdTdT-3’
antisense: 3‘-dTdTGUCACAAGUA|UUCGGCAAGUC-5‘
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Table A.2: qRT-PCR primer
Gene Forward primer Reverse Primer
Egr1 TGACCGCAGAGTCTTTTCCT TGGGTTGGTCATGCTCACTA
CD69 CATGAAGGGTCCTTCCAAGT TGATGGCATTGAGAATGTGTATT
IL8 GGACAAGAGCCAGGAAGAAA AAACTGCACCTTCACACAGAG
IL10RA TGGACCTGTACCACAGCAAT GGTTCACACTGCCAACTGTC
CISH TTCAGGGACCTCGTCCTTT GGCTATGCACAGCAGATCCT
SPRY4 AGCCTGTATTGAGCGGTTTG GGTCAATGGGTAGGATGGTG
PHLDA1 CAAGGAGATCGACTTTCGGT ATGGCCTGACGATTCTTGTA
GDF15 AAGATTCGAACACCGACCTC AGAGATACGCAGGTGCAGGT
MAFF TCTGTGGATCCCCTATCCAG CTTCTGCTTCTGCAGCTCCT
HECW2 GGGAGGAAGCTGACTTTCAC TGAAGAACTCTGGGCTGATG
SOCS1 CTGGGATGCCGTGTTATTTT ACCCCCTCAAGAGGTGAGAA
SLC2A3 CAAGGATGCAGGTGTTCAAG AGTCCTTCTTCCTGCCCTTT
HHEX GGGCAAACCTCTACTCTGGA GCGTCTCGAATTTCTTCTCC
APOL4 CTGGAGGACGTGTCTGGTTA CCTCCTCCAAGGGATCTTC
PIM1 CTGCTCAAGGACACCGTCTA TGGTAGCGGATCCACTCTG
CHAC1 GGAGACACCTTCCATCGG TCATGATCTTCAAGGAGCGT
BHLHB2 GCAAGGAGACCTACAAATTGC TCGGGTAGGAGATCCTTCAG
BCL2L1 GGATGGCCACTTACCTGAAT CTGCTGCATTGTTCCCATAG
SOCS3 GAGGATCCTGGTGACATGCT CAAATGTTGCTTCCCCCTTA
ATF3 GTGCCTGCAGAAAGAGTCG GAGCTCCTCAATCTGAGCCT
ETV5 TTTATGGTCCCAGGGAAATC CTTCAGAATCGTGAGCCAGA
STC2 AGAATACAGCGGAGATCCA AACATTCAAACACGCCACAC
AMIGO2 GAAGTCGGAAGGTGCAAGAG TGAGTCTCTTCCCGGTGTCT
ITPR1 AGGCCGAAGATACCAAGATG ATCCCTGGGTTGAGAAACAG
ERMAP CGGAGGTGGACAATCTTCTT GCTCTTCTCCAGCCTGAGTT
TMEM56 GTGGTCCATCACTTGCAAAC TTTGTCACCAATCACTTTCCA
FAM46B ACCTGAGTGGGCTGAGCT ATGTAGTCCCTGCTCCTCCA
IFIT1 TCTCAGAGGAGCCTGGCTAA TCAGGCATTTCATCGTCATC
LGR4 CCACACTTGGGCCAATAACT TGCTGCTAAGGCTTCTTTCA
p57Kip2 GAGATCAGCGCCTGAGAAGT GGGCTCTTTGGGCTCTAAAT
CYP3A5 TAGGCCCAGTGGGATTTATG CATCTCCATACTGGGCAATG
STS1 ACAAATGGTCCGAAAGATCC TGGGTAAGAGGAAGGATTGG
SHIP2 AAGGCCCTACAGGACATGAG CTTCCCAATCTTGGTCAGGT
GRB2 CTCCCTCTCTGTCAAGTTTGG GTACTTCCCGGCTCCATCT
SHC1 TGATCCCTCCTATGTCAACG ATCTTCGAAGGGCTTCATGT
CRK2 CCCACTACATCATCAACAGCA TCCAGTAAAGCAGGCAATGA
p85alpha TCATTGTCGGATACAGGCAT GGTGGTTTAGGAGGCAGTGT
p85beta AGATGGGCACTATGGCTTCT TCTGGTCCTGCTGGTATTTG
CBL ATTCATTCACAAACCTGGCA TCTGGAGAATGTTCCCATCA
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Table A.4: Expression changes of candidate genes in K562 cells measured by microarray
and qRT-PCR and in U937 cells measured by qRT-PCR
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EGR1 0,011 0,032 0,038 0,004 0,005 0,089 0,012 0,075 0,051
CD69 0,027 0,027 0,010 0,035 0,004 0,805 0,047 0,879 0,878
IL8 0,060 0,026 0,004 0,146 0,059 6,380 2,058 14,753 4,069
IL10RA 0,061 0,036 0,007 0,030 0,009 1,730 0,412 1,432 0,140
CISH 0,064 0,027 0,007 0,044 0,018 0,181 0,040 0,640 0,109
SPRY4 0,085 0,043 0,038 0,003 0,000
PHLDA1 0,108 0,076 0,006 0,113 0,001
GDF15 0,111 0,045 0,017 0,060 0,001
MAFF 0,119 0,105 0,094 0,180 0,041
HECW2 0,123 1,203 1,040 0,844 0,095
SOCS1 0,141 0,087 0,087 0,244 0,206
MYC 0,143
SLC2A3 0,144 0,102 0,048 0,162 0,065
HHEX 0,148 0,092 0,012 0,136 0,050 1,267 0,337 2,558 0,523
APOL4 0,169 0,570 0,226 0,330 0,079
PIM1 0,172 0,106 0,014 0,086 0,003 0,476 0,007 1,654 0,218
CHAC1 0,192 0,114 0,029 0,279 0,080
BHLHB2 0,193 0,107 0,004 0,161 0,056
BCL2L1 0,195 0,152 0,032 0,266 0,143
SOCS3 0,196 0,039 0,001 0,041 0,005 0,623 0,213 0,375 0,352
ATF3 0,210 0,095 0,061 0,137 0,008
ETV5 0,226
STC2 0,239 0,168 0,101 0,256 0,070
AMIGO2 0,241 0,144 0,029 0,218 0,062 3,353 0,410 1,852 1,623
ITPR1 0,274
miRNA21 0,282
ERMAP 2,404 2,819 0,576 3,812 0,149 0,701 0,051 1,382 0,375
TMEM56 2,552 1,623 0,409 3,046 1,489 1,981 0,097 3,192 0,637
FAM46B 3,002 3,723 0,491 7,146 0,560
IFIT1 3,292 16,728 1,800 44,255 6,484 0,599 0,023 1,054 0,524
LGR4 3,349
p57Kip2 3,701 3,319 1,102 3,802 0,261 0,726 0,075 1,238 0,944
CYP3A5 5,509 3,343 0,587 6,825 0,334 2,690 1,384 3,302 1,851
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Table A.6: Influence of drug treatment on IL8 secretion of K562 and U937 cells
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K562
3h
no treatment 172,1 16,2
Dasatinib 150,0 2,7
Nilotinib 155,6 0,1
9h
no treatment 396,6 84,3
Dasatinib 203,6 20,6
Nilotinib 220,1 17,7
24h
no treatment 647,8 156,7
Dasatinib 268,5 15,6
Nilotinib 271,6 12,9
U937
3h
no treatment 33,9 13,9
Dasatinib 32,8 21,4
Nilotinib 27,1 14,9
9h
no treatment 61,6 33,3
Dasatinib 47,2 19,3
Nilotinib 33,9 11,4
24h
no treatment 31,4 7,8
Dasatinib 26,1 6,6
Nilotinib 28,5 2,0
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Table A.7: Influence of drug treatment on IL8 secretion of UT7 p210 and UT7 par cells
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UT7
p210
3h
no treatment 611,3 21,8
Dasatinib 150,3 0,2
Nilotinib 221,1 0,6
9h
no treatment 841,2 9,4
Dasatinib 276,4 10,6
Nilotinib 369,6 8,1
24h
no treatment 1057,0 20,4
Dasatinib 355,5 7,3
Nilotinib 471,3 2,7
UT7
par
3h
no treatment 108,0 5,1
Dasatinib 93,8 31,9
Nilotinib 66,1 7,1
9h
no treatment 323,4 15,3
Dasatinib 261,4 7,6
Nilotinib 236,6 10,8
24h
no treatment 494,1 13,4
Dasatinib 455,0
Nilotinib 426,4 12,3
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Table A.8: Influence of Imatinib therapy on IL8 levels in serum of CML patients
Patient Time of therapy IL8 (ng/ml serum) standard deviation
CML patient 1
diagnosis 3,788 0,750
1 month 0,053 0,016
3 months * 0,104 0,047
CML patient 2
diagnosis 1,786 0,108
1 month 1,585 0,010
3 months 0,086 0,004
12months 1,527 0,035
CML patient 3
diagnosis 0,576 0,026
diagnosis 0,361 0,011
1 month 0,125 0,013
3 months 0,370 0,013
24 months * 0,128 0,011
CML patient 4
diagnosis 0,535 0,026
1 month 0,179 0,013
3 months * 0,059 0,006
healthy
donors
ctr 0,108 0,008
ctr 0,058 0,002
* complete cytogenetic response
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